5. Conclusion
These findings indicate the possible potential of GLP based therapy, as
an add-on therapy to sulfasalazine in ameliorating IBD in A-A model of
IBD in mice through regulating the secretion of the transcription factor
NFκB- dependent inflammatory cytokines, decreasing the oxidative stress
injury, promoting tissue repair of injured epithelium with better
tolerated side effects. However, further long-term studies to evaluate
the tolerability and efficacy of these drugs are required and the
decision to choose any of these drugs should be tailored according to
the general status of each patient and the presence of any compelling
indication or contraindication.